2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2172

Impact of Biologic and Non-Biologic Treatment on the Incidence of Traditional Cardiovascular Risk Factors Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis
Abstract Number: 2173

Patient Reported Disease Activity and Efficacy of Biologic Therapy in Patients with Psoriatic Arthritis. an Observational Study of 107 Patients of the Estonian Society for Rheumatology Biologic Therapy Register during 2008-2014
Abstract Number: 2174

Effect of Anti-Rheumatic Treatment on Selenium Levels in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Abstract Number: 2175

Comparisons of Patients Prescribed Biosimilars or BIO-Originators for Autoimmune Diseases in Germany
Abstract Number: 2176

Comorbidities and DMARD, NSAID and Steroid Use in a Real Life Cohort of 8,981 Patients with Psoriatic Arthritis
Abstract Number: 2177

Specificity of Spinal Pain Features in Assessment and Classification of Spondyloarthritis
Abstract Number: 2178

Statin Use and Increased Risk of Musculoskeletal Conditions: A Retrospective Cohort Study with Propensity Score-Matching
Abstract Number: 2179

What Are the Risk Factors for Knee Pain, Radiographic Knee Osteoarthritis and Total Knee Replacement in Professional Footballers?
Abstract Number: 2180

Association of Anterior Cruciate Ligament/Meniscal Injury with Knee Function, Knee Pain, and Knee Osteoarthritis in Military Officers
Abstract Number: 2181

High Dietary Fiber Intake Is Associated with Lower Likelihood of Severe Knee Pain Trajectory
Abstract Number: 2182

Levels of Severity of Hip and Knee OA – Validation of Lay Descriptions
Abstract Number: 2183

The Electronic Osteoarthritis Knee and Hip Quality of Life (OAKHQOL) Questionnaire: A Useful and Valid Alternative to Measure Health-Related Quality of Life in Knee Osteoarthritis
Abstract Number: 2184

Evidence Based Physical Activity Threshold to Predict Improved/High Function in Older Adults with Lower Extremity Conditions: The Osteoarthritis Initiative
Abstract Number: 2185

Prevalence and Trends in Prescribed Opioid Use Among US Adults with Arthritis, 2008-2013, Medical Expenditure Panel Survey
Abstract Number: 2186

Analgesic Use and Subsequent Risk of Falls in Participants with or at Risk of Knee Osteoarthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].